STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCRX
  4. [Form 4] Pacira BioSciences, Inc. Insider Trading Activity

Pacira BioSciences (PCRX) director receives RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pacira BioSciences director Alethia Young reported receiving equity compensation. On June 10, 2026, she was granted 6,405 restricted stock units, each representing one future share of common stock, and 10,891 stock options with an exercise price of $23.42 per share.

Both the restricted stock units and options vest on June 10, 2027, provided she remains in continuous service with Pacira through that date. Following the grant, she directly holds 17,798 shares of common stock, plus the newly granted options for 10,891 additional shares.

Positive

  • None.

Negative

  • None.
Insider Young Alethia
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 10,891 $0.00 --
Grant/Award Common Stock 6,405 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 10,891 shares (Direct, null); Common Stock — 17,798 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Restricted stock units granted 6,405 units Awarded June 10, 2026; vest June 10, 2027
Stock options granted 10,891 options Awarded June 10, 2026; expire June 10, 2036
Option exercise price $23.42 per share Exercise price for 10,891 stock options
Vesting date June 10, 2027 Vesting for RSUs and stock options, contingent on service
Shares held after grant 17,798 shares Common stock directly held following the transaction
Underlying option shares 10,891 shares Common shares underlying the granted stock options
restricted stock units financial
"Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
continuous service financial
"provided that the reporting person remains in continuous service with the issuer through the vesting date"
stock option financial
"The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "23.4200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests financial
"Represents restricted stock units that vest on June 10, 2027"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Young Alethia
(Last)(First)(Middle)
C/O PACIRA BIOSCIENCES, INC.
2000 SIERRA POINT PARKWAY, SUITE 900
(Street)
BRISBANE CALIFORNIA 94005
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/10/2026A6,405(1)A$017,798D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$23.4206/10/2026A10,89106/10/2027(2)06/10/2036Common Stock10,891$010,891D
Explanation of Responses:
1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
2. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Remarks:
/s/ Kristen Williams, Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pacira BioSciences (PCRX) director Alethia Young report in this Form 4?

Alethia Young reported receiving equity compensation from Pacira BioSciences. She was granted 6,405 restricted stock units and 10,891 stock options, both awarded on June 10, 2026, as part of her director compensation package.

How many Pacira BioSciences (PCRX) shares does Alethia Young hold after these grants?

After the reported grants, Alethia Young directly holds 17,798 shares of Pacira common stock. This total reflects her ownership following the June 10, 2026 equity awards disclosed in the Form 4 filing.

What are the terms of Alethia Young’s restricted stock units from Pacira BioSciences (PCRX)?

Young received 6,405 restricted stock units that vest on June 10, 2027. Each unit converts into one share of Pacira common stock, contingent on her remaining in continuous service with the company until the vesting date.

What are the key details of Alethia Young’s Pacira BioSciences (PCRX) stock options?

She received 10,891 stock options with an exercise price of $23.42 per share. These options vest on June 10, 2027, and remain exercisable until June 10, 2036, assuming she continues service through the vesting date.

Did Alethia Young buy or sell Pacira BioSciences (PCRX) shares on the market?

The Form 4 shows no open-market purchases or sales. Instead, it reports non-cash equity awards: restricted stock units and stock options granted as compensation, with vesting dependent on her continued service to Pacira BioSciences.